Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome <i>bc</i> <sub>1</sub> Complex-Reference-Cited by-同舟云学术

Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc ₁ Complex

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gries Raphael¹²³^ORCID,Dal Molin Michael¹²^ORCID,Chhen Jason¹²,van Gumpel Edeltraud¹²,Dreyer Viola⁴⁵^ORCID,Niemann Stefan⁴⁵^ORCID,Rybniker Jan¹²³^ORCID

Affiliation:

1. Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany

2. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

3. German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

4. Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany

5. German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany

Abstract

Drug-resistant tuberculosis is a global health care threat calling for novel effective treatment options. Here, we report on two novel cytochrome bc 1 inhibitors (MJ-22 and B6) targeting the Mycobacterium tuberculosis respiratory chain with excellent intracellular activities in human macrophages. Both hit compounds revealed very low mutation frequencies and distinct cross-resistance patterns with other advanced cytochrome bc 1 inhibitors.

Funder

Deutsche Forschungsgemeinschaft

Deutsches Zentrum für Infektionsforschung

EC | Horizon 2020 Framework Programme

Bundesministerium für Bildung und Forschung

UoC | Center for Molecular Medicine Cologne, University of Cologne

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00251-23

Reference19 articles.

1. WHO. 2022. Global tuberculosis report. WHO, Geneva, Switzerland.

2. Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis

3. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?

4. QcrB in Mycobacterium tuberculosis : The new drug target of antitubercular agents

5. Bedaquiline: First FDA-approved tuberculosis drug in 40 years